Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders

News
2023
2022
Archive

February 2, 2023

Escient Pharmaceuticals Announces IND Clearance by FDA to Start Phase 1 Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist for Mast Cell Mediated Disorders
February 2, 2023

Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program
January 31, 2023

Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
January 31, 2023

scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
January 31, 2023

Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
January 27, 2023

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
January 23, 2023

IDEAYA Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma
January 19, 2023

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
January 18, 2023

Wildcat Discovery Signs Joint Development Agreement with BMW Group to Speed Next Generation Battery Technology to the Market
January 18, 2023

Pear Therapeutics Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

1
2
3
…
106
Next Page »

© 2023 5AM Venture Management LLC